Crinetics Pharmaceuticals, Inc. Total Liabilities
Crinetics Pharmaceuticals, Inc. (CRNX) had Total Liabilities of $129.92 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-08-03
- 2026-06-30: Liabilities $129.92M.
- 2026-03-31: Liabilities $120.68M.
- 2025-12-31: Liabilities $134.17M.
- 2025-09-30: Liabilities $123.86M.
| Period end | Liabilities |
|---|---|
| 2026-06-30 | $129.92M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $120.68M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $134.17M 10-Q · filed 2026-08-03 |
| 2025-09-30 | $123.86M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $118.05M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $107.33M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $109.79M 10-K · filed 2026-02-26 |
| 2024-09-30 | $104.39M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $104.77M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $103.22M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $96.25M 10-K · filed 2025-02-27 |
| 2023-09-30 | $93.79M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $39.14M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $33.68M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $35.85M 10-K · filed 2024-02-28 |
| 2022-09-30 | $33.51M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $35.57M 10-Q · filed 2022-08-12 |
| 2022-03-31 | $30.24M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $19.07M 10-K · filed 2023-02-28 |
| 2021-09-30 | $15.77M 10-Q · filed 2021-11-05 |
| 2021-06-30 | $15.49M 10-Q · filed 2021-08-10 |
| 2021-03-31 | $14.07M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $14.53M 10-K · filed 2022-03-30 |
| 2020-09-30 | $13.10M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $14.35M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $15.45M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $13.24M 10-K · filed 2021-03-30 |
| 2019-09-30 | $12.99M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $13.05M 10-Q · filed 2019-08-13 |
| 2019-03-31 | $14.37M 10-Q · filed 2019-05-13 |
| 2018-12-31 | $11.19M 10-K · filed 2020-03-09 |
| 2018-09-30 | $9.16M 10-Q · filed 2018-11-13 |
| 2018-06-30 | $6.91M 10-Q · filed 2018-08-30 |
| 2017-12-31 | $920.00K 10-K · filed 2019-03-13 |